Literature DB >> 6423039

Impaired elimination of metronidazole in decompensated chronic liver disease.

G Farrell, L Zaluzny, J Baird-Lambert, M Cvejic, N Buchanan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6423039      PMCID: PMC1550041          DOI: 10.1136/bmj.287.6408.1845

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


× No keyword cloud information.
  5 in total

Review 1.  Drug therapy: metronidazole.

Authors:  J Koch-Weser; P Goldman
Journal:  N Engl J Med       Date:  1980-11-20       Impact factor: 91.245

2.  Rectal administration of metronidazole provides therapeutic plasma levels in postoperative patients.

Authors:  L Ioannides; A Somogyi; J Spicer; B Heinzow; N Tong; C Franklin; A McLean
Journal:  N Engl J Med       Date:  1981-12-24       Impact factor: 91.245

3.  High-pressure liquid chromatographic analysis of antipyrine in small plasma samples.

Authors:  L Shargel; W M Cheung; A B Yu
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

4.  Disposition of oral metronidazole in hepatic cirrhosis and in hepatosplenic schistosomiasis.

Authors:  T K Daneshmend; M Homeida; C M Kaye; A A Elamin; C J Roberts
Journal:  Gut       Date:  1982-10       Impact factor: 23.059

5.  Drug metabolism in liver disease. Identification of patients with impaired hepatic drug metabolism.

Authors:  G C Farrell; W G Cooksley; P Hart; L W Powell
Journal:  Gastroenterology       Date:  1978-10       Impact factor: 22.682

  5 in total
  2 in total

Review 1.  Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.

Authors:  A H Lau; N P Lam; S C Piscitelli; L Wilkes; L H Danziger
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

2.  Accuracy and clinical utility of simplified tests of antipyrine metabolism.

Authors:  G C Farrell; L Zaluzny
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.